Toronto Innovation Acceleration Partners

Grey Matter Neurosciences is a neurotechnology company specializing in the development of innovative medical devices and drug-device combinations to address age-related brain disorders, with a primary focus on dementia. Their flagship technology is a portable ultrasound helmet, designed to non-invasively enhance brain function in seniors with Alzheimer's disease.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

HDAX Therapeutics is focused on developing innovative small molecule therapeutics aimed at treating conditions driven by HDAC6, particularly in the realms of cardiovascular and neurological diseases. By addressing the root causes of these conditions, the company seeks to improve patient outcomes significantly. Their approach involves a unique targeted therapeutics platform that utilizes a two-site binding mechanism for HDAC6, which allows for the delivery of treatments that are both safe and effective. This strategy is designed to meet the substantial unmet medical needs associated with neuropathies and cardiometabolic diseases.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.

Spero Analytics specializes in designing and deploying wireless mesh networks for continuous environmental monitoring in remote and off-grid locations. Their scalable sensor arrays, capable of covering vast areas and adapting to various sensor types, require no telecommunications infrastructure. Key features include self-healing network capabilities and cold climate adaptability, reducing maintenance burden. The company focuses on automated greenhouse gas monitoring in landfills, with installations in Ontario, and is expanding to petroleum facilities and potash mines through collaborations with Environment Canada and proof-of-concept projects. Spero Analytics has raised $210,000, secured design partners, and made sales to government and international clients. Their mission is to become the industry standard for remote environmental monitoring.

Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Medly offers an AI-powered platform for managing multiple chronic conditions. Medly's vision is to become the leading platform for managing multiple chronic conditions (MCCs), with identified target conditions including Heart Failure, Depression (Mental Health), Diabetes, and Hypertension.

NerveX Neurotechnologies focuses on the development of innovative neuromodulation devices aimed at repairing and enhancing the nervous system. Its flagship product, ANIMO, serves as a platform for implanting proprietary machine learning and responsive electrical neuromodulation technology. This technology is designed to improve sensory functions and specifically aids in addressing canine epilepsy disorder, enabling affected dogs to regain normalcy in their lives. Through its advancements, NerveX seeks to contribute to the field of neurotechnology by providing effective solutions for both animals and potentially broader applications in nervous system modulation.

Genetics Adviser is a digital health company that offers a web-based platform designed to enhance genetic counseling services. The platform provides patients with access to educational content and resources, enabling them to better understand their genetic health before consulting with clinicians. This pre-consultation preparation allows for more efficient and patient-centered clinical interactions, as complex information can be reviewed at home, reserving clinical time for personalized discussions. The platform also facilitates secure messaging between patients and clinicians, and enables patients to download summaries of their sessions and results.

Mazlite is a developer of an industrial IoT platform focused on spray monitoring and digitization in hazardous environments. The company provides unique hardware sensors and web-based software that facilitate real-time analytics and cloud-based data management. This technology is particularly beneficial for industries such as automotive paint and pharmaceuticals, allowing manufacturers to monitor spray applications effectively. By utilizing a physics-based artificial intelligence system, Mazlite enables manufacturers to identify and resolve product quality issues, enhance sustainability, and reduce material and energy waste, ultimately minimizing scraps and repairs.

Damona Pharmaceuticals is a pre-clinical biotechnology company focused on developing treatments for cognitive deficits associated with various brain disorders and aging. The company aims to create small molecule therapeutics that address cognitive symptoms and improve normal life functions, particularly for underserved and understudied populations in mental health and aging. By leveraging its innovative research platform, Damona Pharmaceuticals seeks to offer solutions that not only treat but potentially reverse cognitive impairments, addressing previously unresolvable symptoms and enhancing the quality of life for affected individuals.

Damona Pharmaceuticals is a pre-clinical biotechnology company focused on developing treatments for cognitive deficits associated with various brain disorders and aging. The company aims to create small molecule therapeutics that address cognitive symptoms and improve normal life functions, particularly for underserved and understudied populations in mental health and aging. By leveraging its innovative research platform, Damona Pharmaceuticals seeks to offer solutions that not only treat but potentially reverse cognitive impairments, addressing previously unresolvable symptoms and enhancing the quality of life for affected individuals.

Pearl Interactives specializes in creating interactive media tailored for children of all abilities, focusing on wellness, play, and learning. The company has developed a unique platform that includes its flagship product, Bootle Blast, which combines innovative mixed reality technology with engaging video game experiences. This system targets children and youth with neuromotor conditions, facilitating exercises that aim to improve their functional abilities. Additionally, the platform incorporates real-life musical instruments and touch-free interactive games, promoting shared musical play while also helping to alleviate anxiety. Through these offerings, Pearl Interactives strives to foster an inclusive environment that enhances the developmental opportunities for children.

Tabiat operates a software-as-a-service (SaaS) platform that specializes in artificial intelligence-driven remote patient monitoring. The platform is designed to enhance patient outcomes by providing actionable insights that aid clinicians in their decision-making processes. By delivering timely and relevant data, Tabiat enables healthcare providers to effectively assess the condition of multiple patients simultaneously, allowing them to focus on those who require immediate attention. This not only improves the quality of care but also helps to reduce hospitalization costs while creating additional revenue opportunities for healthcare professionals.

PhenoTips is a computer software company based in Ontario, Canada, founded in 2014. It specializes in providing solutions for clinical genetics, phenotyping, and human phenotype ontology. The company offers software designed for clinical use that integrates seamlessly with existing electronic health records. PhenoTips' technology aims to enhance diagnostic accuracy and standardize phenotype recording, facilitating the application of genomic medicine in clinical decision-making and diagnosis.

PhenoTips is a computer software company based in Ontario, Canada, founded in 2014. It specializes in providing solutions for clinical genetics, phenotyping, and human phenotype ontology. The company offers software designed for clinical use that integrates seamlessly with existing electronic health records. PhenoTips' technology aims to enhance diagnostic accuracy and standardize phenotype recording, facilitating the application of genomic medicine in clinical decision-making and diagnosis.

Quantum Bridge is dedicated to enhancing security for organizations that require the protection of highly confidential and classified information. The company develops proprietary software and quantum repeater hardware aimed at improving quantum communications. Its focus is on the commercialization of quantum and quantum-inspired products, which include secure communication tools and a distributed symmetric key exchange system. These innovations are designed to ensure that communication remains quantum-safe, thereby reinforcing network and endpoint security. By providing solutions that enhance resilience in existing networks, Quantum Bridge aims to meet the growing demand for unbreakable security in today's digital landscape.

Bright Angel Therapeutics focuses on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the effectiveness of existing antifungal therapies and eliminate drug resistance by specifically targeting the stress responses that fungi rely on for survival and virulence. By addressing these critical factors, Bright Angel Therapeutics seeks to mitigate the common occurrence of clinical resistance, which is a major contributor to the significant morbidity and mortality associated with various fungal infections. Through its research and development efforts, the company endeavors to improve patient outcomes in the face of challenging fungal pathogens.

Radiant Biotherapeutics is an innovative company focused on developing a modular platform for multi-valent and multi-specific therapeutics. This platform aims to advance antibody engineering by producing multi-functional biologics capable of addressing challenging diseases, including cancer, autoimmune disorders, and infectious diseases. By leveraging enhanced binding power and multi-specificity, Radiant Biotherapeutics seeks to create potent therapeutics that have the potential to significantly improve treatment outcomes for patients. The company is committed to delivering transformative therapies through its cutting-edge approach to antibody technology.

Phenomic AI Inc. is a biotechnology company based in Toronto, Canada, founded in 2017. The company specializes in developing artificial intelligence solutions to enhance drug discovery and the creation of therapies for cancer. Its innovative platform utilizes AI, computer vision, and high-content screening to analyze phenotypes in complex disease models, such as high-content co-culture and three-dimensional assays. By focusing on the tumor stroma, Phenomic AI aims to optimize the discovery and development of new medicines, streamlining the process for pharmaceutical companies to identify potential drug candidates more effectively.

Hypercare operates a healthcare coordination platform designed to enhance clinical communication and collaboration among providers. This platform addresses the growing complexity of patient care, which often requires input from multiple providers across various departments and specialties. Traditional communication methods in hospitals, such as switchboards and pagers, have proven ineffective, resulting in delays in patient care and suboptimal outcomes. Hypercare's solution facilitates secure and efficient communication among healthcare professionals in diverse settings, including hospitals, long-term care facilities, and community care organizations. By enabling providers to connect quickly and effectively, Hypercare aims to minimize interruptions and improve patient-centered care while ensuring the protection of personal health information.

Phycus Biotechnologies Inc. is a Toronto-based company founded in 2017 that specializes in producing ingredients for the cosmetics and personal care industries, including bioglycolic acid and AHA ferment products. Additionally, the company operates a bio-conversion platform that focuses on capturing and converting carbon dioxide from large-scale emitters into valuable chemical building blocks. By employing microbial technology and metabolic engineering techniques, Phycus aims to provide sustainable alternatives for recycling carbon dioxide into fuels and chemicals. This innovative approach not only supports various industrial applications but also contributes to reducing the overall greenhouse gas footprint, aligning with environmental sustainability goals.

Reeddi is a climate technology company focused on creating innovative solutions for sustainable, clean, and affordable electricity. The company targets energy-poor regions, aiming to provide electricity where it is currently unavailable. Reeddi's technology is designed to generate, distribute, and store clean energy, delivering both alternating current (AC) and direct current (DC). This versatility allows their devices to power a range of applications, from mobile phones to household electronics, thereby enhancing energy access for individuals, households, and businesses. By offering an alternative to fuel-based electricity generation, Reeddi seeks to mitigate the health and environmental risks associated with traditional energy sources in operating communities.

Bright Angel Therapeutics focuses on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the effectiveness of existing antifungal therapies and eliminate drug resistance by specifically targeting the stress responses that fungi rely on for survival and virulence. By addressing these critical factors, Bright Angel Therapeutics seeks to mitigate the common occurrence of clinical resistance, which is a major contributor to the significant morbidity and mortality associated with various fungal infections. Through its research and development efforts, the company endeavors to improve patient outcomes in the face of challenging fungal pathogens.

ODAIA is a company that has developed an AI-powered Customer Data Platform specifically for the Life Sciences industry. This innovative platform integrates process mining, customer journey mapping, and artificial intelligence to provide commercial insights and automate processes. By leveraging data analysis, ODAIA's solution enables pharmaceutical commercial teams to enhance personalized selling and ensure that therapeutics reach the patients who require them. The platform aims to streamline decision-making and improve the effectiveness of commercial strategies in the healthcare sector.

CoHealth is a content creation and distribution platform tailored for health organizations, including healthcare providers and systems. The platform facilitates the development and dissemination of health-related content, enabling these organizations to effectively reach health consumers. It offers features such as hospital information, medication reminders, and personalized task recommendations through a collaboration between personal health managers and healthcare providers. By creating customized digital care pathways for various health conditions, CoHealth ensures that patients receive comprehensive aftercare support following their hospital discharge.

Bright Angel Therapeutics focuses on developing innovative treatments for drug-resistant and life-threatening fungal infections. The company aims to enhance the effectiveness of existing antifungal therapies and eliminate drug resistance by specifically targeting the stress responses that fungi rely on for survival and virulence. By addressing these critical factors, Bright Angel Therapeutics seeks to mitigate the common occurrence of clinical resistance, which is a major contributor to the significant morbidity and mortality associated with various fungal infections. Through its research and development efforts, the company endeavors to improve patient outcomes in the face of challenging fungal pathogens.

Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Based in Toronto, Canada, the company utilizes a proprietary platform for induced pluripotent stem cell (iPSC) technology that allows for precision control of Notch signaling, which is essential for T cell development. This innovative approach addresses critical limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. Notch Therapeutics aims to provide targeted treatments for conditions such as non-Hodgkin lymphoma, leukemia, and multiple myeloma, facilitating advancements in the treatment of complex disease systems. Established in 2018, the company is positioned at the forefront of next-generation cancer therapies.

Flybits Inc., based in Toronto, Canada, specializes in developing a platform that enhances customer experiences in the financial services sector through contextualization. The company's advanced solution allows banks to deliver personalized content, products, and offers tailored to individual customer needs in real-time. By leveraging extensive data and sensing capabilities, Flybits enables financial institutions to design, launch, and evaluate data-driven experiences that provide relevant information while maintaining customer privacy. This approach fosters a deeper relationship between customers and their financial institutions, ultimately driving product awareness and adding significant value to users' interactions.

Cohesys develops innovative surgical adhesives inspired by nature, specifically designed for craniomaxillofacial (CMF) fracture fixation. The company's biodegradable bone tape offers a flexible and resorbable solution that can effectively replace traditional titanium screws. By streamlining the fracture fixation process, Cohesys' technology aims to enhance patient outcomes and reduce the risks associated with bone fractures. Its advanced adhesive system contributes to safer and faster surgical procedures, ultimately improving the overall efficiency of treatment for facial fractures.

Mutuo Health Solutions specializes in developing artificial intelligence technology to enhance healthcare communication. The company offers a medical device that captures dialogues between patients and clinicians using any microphone. This AI-driven solution employs speech recognition and natural language processing to automatically generate clinical notes and suggest actions for electronic medical records in real time. By streamlining the documentation process, Mutuo Health Solutions allows medical professionals to concentrate more on patient care, thereby improving overall healthcare efficiency and effectiveness.

Bitnobi is a software company focused on designing and developing a data-sharing platform primarily for the healthcare and finance sectors. The platform enables secure and privacy-protected access to big data, eliminating the need to create multiple copies of source data. By centering on launching data jobs for end users, Bitnobi facilitates efficient data sharing while maintaining data integrity and security. The company's services encompass data management, cloud computing, and cybersecurity, providing comprehensive solutions tailored to the specific needs of its clients. An online inquiry form is available on their website for potential customers seeking more information.

Micellae Delivery Systems is a pharmaceutical manufacturing company specializing in innovative drug delivery systems aimed at enhancing the solubility and bioavailability of fat-soluble compounds, particularly cannabinoids. The company has developed proprietary formulation platforms that facilitate the creation of various dosage forms, including liquids, concentrates, gels, and powders. These formulations cater to a diverse range of applications in medical and recreational cannabis, as well as in the pharmaceutical, nutraceutical, and cosmetic sectors. By focusing on cost-effective and sustainable technologies, Micellae Delivery Systems provides clients with healthier and safer options for cannabis delivery.

Lorica Cybersecurity specializes in advanced encryption technologies that enable secure and privacy-preserving data analytics on a large scale in the cloud. The company’s innovative platform utilizes machine learning and cryptography, including fully homomorphic encryption, to facilitate private collaboration and data discovery. Lorica's solutions allow enterprises to interact with encrypted data throughout their entire value chain—on premises, in the cloud, and across third parties—without exposing sensitive information to risk. By focusing on secure insights and seamless collaboration, Lorica aims to enhance innovation while ensuring compliance with regulatory standards. The company's mission is to unlock the value of data, providing trusted tools that protect both privacy and intellectual property in an increasingly digital environment.

NURO is the manufacturer of the NUOS, PAD, KOMPOS and MENTIS surgery-free neurological platforms. For more information, please visit www.nuro.world.

Appulse Power Inc. is a semiconductor design company based in Toronto, Canada, specializing in application-specific integrated circuits (ASIC) for power management. Founded in 2015 and later acquired by The Silanna Group Pty. Ltd. in 2018, Appulse Power focuses on innovative AC/DC power conversion technologies tailored for the Internet of Things and smart energy markets. The company's products aim to enhance efficiency, reduce costs, and minimize the physical size of power supplies compared to existing solutions. By addressing the challenges associated with traditional AC/DC converters, Appulse Power enables the consolidation of electronic device chargers into a single, compact unit, significantly lowering size and power loss.

Upchain is a provider of cloud-based product lifecycle management (PLM) and product data management (PDM) solutions, established in 2015. The company aims to transform the way PLM is approached by making it more accessible to all participants in the supply chain, rather than focusing solely on large multinational corporations. Upchain's software facilitates collaboration across decentralized product value chains, offering features such as item management, version control, change management, bills of materials management, file compliance, and integration with computer-aided design tools. This comprehensive approach enables manufacturers operating within complex value chains to enhance revenue, reduce costs, and improve product quality, thereby streamlining the entire lifecycle from initial design to final assembly.

Dalriada Therapeutics Inc. is a Canadian company based in Mississauga, established in 2016. It specializes in the development of novel small molecule inhibitors targeting various medical conditions, including oncology, pain modulation, and neurodegenerative and neuroinflammatory disorders. The company employs a TURN-KEY model that integrates research and development with business strategy and intellectual property management, thereby supporting global innovators in the pharmaceutical industry.

Zucara Therapeutics Inc. is a biotechnology company based in Toronto, Canada, with an additional office in Vancouver. Founded in 2014, the company focuses on developing innovative therapeutics aimed at preventing hypoglycemia, or low blood sugar, in patients with diabetes. Its lead pre-clinical technology targets somatostatin type 2 receptors in the pancreas, which are inadequately regulated in individuals with Type 1 diabetes. By blocking these receptors, Zucara's treatment aims to prevent hypoglycemia and restore natural glucose levels in the bloodstream. This approach represents a significant advancement over existing therapies, which typically only address hypoglycemia after it has occurred, rather than preventing it from happening in the first place.

Bitnobi is a software company focused on designing and developing a data-sharing platform primarily for the healthcare and finance sectors. The platform enables secure and privacy-protected access to big data, eliminating the need to create multiple copies of source data. By centering on launching data jobs for end users, Bitnobi facilitates efficient data sharing while maintaining data integrity and security. The company's services encompass data management, cloud computing, and cybersecurity, providing comprehensive solutions tailored to the specific needs of its clients. An online inquiry form is available on their website for potential customers seeking more information.

Hypercare operates a healthcare coordination platform designed to enhance clinical communication and collaboration among providers. This platform addresses the growing complexity of patient care, which often requires input from multiple providers across various departments and specialties. Traditional communication methods in hospitals, such as switchboards and pagers, have proven ineffective, resulting in delays in patient care and suboptimal outcomes. Hypercare's solution facilitates secure and efficient communication among healthcare professionals in diverse settings, including hospitals, long-term care facilities, and community care organizations. By enabling providers to connect quickly and effectively, Hypercare aims to minimize interruptions and improve patient-centered care while ensuring the protection of personal health information.

Structura Biotechnology specializes in developing a cryo-electron microscopy image analysis platform that enhances the study of biological systems. The platform employs machine learning technology to facilitate the detailed analysis and 3D reconstruction of atomic structures of proteins, biomolecule complexes, and viruses. This capability allows researchers to investigate membrane proteins, ion channels, G protein-coupled receptors, and drug targets with ligands bound. By providing advanced tools for cryo-electron microscopy data analysis, Structura Biotechnology supports healthcare professionals in creating new medicines and improving drug development processes.

Appulse Power Inc. is a semiconductor design company based in Toronto, Canada, specializing in application-specific integrated circuits (ASIC) for power management. Founded in 2015 and later acquired by The Silanna Group Pty. Ltd. in 2018, Appulse Power focuses on innovative AC/DC power conversion technologies tailored for the Internet of Things and smart energy markets. The company's products aim to enhance efficiency, reduce costs, and minimize the physical size of power supplies compared to existing solutions. By addressing the challenges associated with traditional AC/DC converters, Appulse Power enables the consolidation of electronic device chargers into a single, compact unit, significantly lowering size and power loss.

QD Solar Inc. is a Canadian company based in Toronto that specializes in the development of advanced photovoltaic cells utilizing colloidal quantum dot technology. Founded in 2014 as a spinoff from the University of Toronto, QD Solar combines silicon solar cells with infrared solar cells in a hybrid architecture. This innovative approach allows the company to capture a broader range of the solar spectrum compared to traditional silicon cells alone. By enhancing the efficiency of solar energy harvesting, QD Solar aims to address the competitive pressures in the solar photovoltaic market, where differentiation through improved performance at competitive costs is essential. The company's technology promotes sustainable development and aims to increase the adoption of renewable energy sources.

Hypercare operates a healthcare coordination platform designed to enhance clinical communication and collaboration among providers. This platform addresses the growing complexity of patient care, which often requires input from multiple providers across various departments and specialties. Traditional communication methods in hospitals, such as switchboards and pagers, have proven ineffective, resulting in delays in patient care and suboptimal outcomes. Hypercare's solution facilitates secure and efficient communication among healthcare professionals in diverse settings, including hospitals, long-term care facilities, and community care organizations. By enabling providers to connect quickly and effectively, Hypercare aims to minimize interruptions and improve patient-centered care while ensuring the protection of personal health information.

Fibrocor Therapeutics L.P. is a biotechnology company based in Toronto, Canada, established in 2017. The company specializes in the development of tissue-specific therapeutics aimed at addressing the underlying causes of fibrotic diseases affecting the kidneys and other organs. Fibrocor focuses on identifying and targeting critical pathways involved in the fibrogenic process, utilizing patient-derived tissue samples to uncover novel disease targets. The company has advanced a lead program and has partnered with Evotec to facilitate the development of innovative therapeutic molecules.

LegUp Computing Inc. is a Toronto-based company that develops a cloud platform enabling software developers to program, deploy, scale, and manage field-programmable gate array (FPGA) devices. Founded in 2015 by a team including Dr. Andrew Canis and Professor Jason Anderson, the platform originated from research at the University of Toronto and focuses on providing a novel programming model for threaded C/C++ software. This model allows for efficient processing of low-latency database, real-time analytics, and machine learning workloads by leveraging FPGA devices connected to high-bandwidth networks. LegUp Computing aims to facilitate the acceleration of high-performance applications, thereby enhancing the capabilities of developers working with cloud-based and embedded compute systems. The company operates as a subsidiary of Microchip Technology Incorporated.

HippoCamera is an online application aimed at enhancing the memory recall of older adults through engaging reminiscence activities. The platform employs a unique approach that simulates the function of the hippocampus, a critical area of the brain involved in memory processing. By combining enjoyable activities with proven cognitive benefits, HippoCamera helps users improve their ability to recall and remember significant events from their lives, ultimately promoting cognitive health and well-being among the elderly.

Zucara Therapeutics Inc. is a biotechnology company based in Toronto, Canada, with an additional office in Vancouver. Founded in 2014, the company focuses on developing innovative therapeutics aimed at preventing hypoglycemia, or low blood sugar, in patients with diabetes. Its lead pre-clinical technology targets somatostatin type 2 receptors in the pancreas, which are inadequately regulated in individuals with Type 1 diabetes. By blocking these receptors, Zucara's treatment aims to prevent hypoglycemia and restore natural glucose levels in the bloodstream. This approach represents a significant advancement over existing therapies, which typically only address hypoglycemia after it has occurred, rather than preventing it from happening in the first place.

Xor Labs Toronto is a pioneering company in the field of personalized medicine for organ transplantation, focusing specifically on lungs. The company develops advanced medical devices aimed at supporting lung transplantation, particularly for patients suffering from critical conditions such as pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and chronic obstructive pulmonary disease. By enhancing the availability of donated lungs for transplantation, Xor Labs aims to significantly improve patient outcomes and reduce mortality rates associated with these diseases. Through its innovative approach, the company is transforming the landscape of organ transplantation on a global scale.

Purchs is an omnichannel platform that facilitates efficient sourcing and billing for merchants by integrating conversational commerce and artificial intelligence. Merchants can effortlessly complete transactions through text by scanning a Product UPC code with their smartphones, eliminating the need for logins or traditional checkout processes. For vendors, Purchs provides a comprehensive e-commerce solution tailored for B2B retail sales, allowing them to list products at custom prices, manage inventory and deliveries, and automate payment processes, all from a single platform. Additionally, the platform simplifies wholesale distribution and direct-to-store delivery, helping clients reduce both distribution costs and their carbon footprint.

Radialis develops an organ-targeted positron emission tomography (PET) imaging system aimed at providing high-definition and low-dose imaging solutions for oncology, neurology, and cardiology. Its technology significantly enhances the efficiency of detecting radiotracers compared to conventional PET systems, which allows for improved cancer detection. The system has received broad FDA clearance in the United States for imaging and measuring injected positron-emitting radiopharmaceuticals. Currently, the leading application of this technology is in the high-resolution imaging of primary solid tumors, assisting in treatment planning as a complement to traditional staging PET/CT without requiring additional radiotracer. Furthermore, Radialis is exploring opportunities for early detection of cancer and Alzheimer's disease using low-dose imaging techniques in high-risk populations.

Knitt Labs is a Toronto-based technology start-up that aims to address energy waste by transforming how power is utilized and managed. The company has developed innovative technology that leverages big data to optimize electricity consumption, helping clients reduce energy waste and save on costs. By integrating Internet of Things (IoT) devices, Knitt Labs enables users to gain better insights into their energy usage, ultimately redefining individual power management practices.

Crowd2Know operates in the area of stakeholder engagement. We bring organizations operating in urban development closer to their customers, citizens and end users by providing a platform for listening, analyzing, and effectively communicating with each other. We achieve this through a systematic process using a suite of software products and expert services that facilitate the analysis of social media, project documents, and other records. Using our urban infrastructure knowledge base and set of analysis algorithms we provide a real-time mapping of stakeholders, discussion topics, and relative alignment of opinions which drive consistent recommendations for decision makers.

Blue J is a developer of a legal research platform that aims to predict court outcomes, enhancing the efficiency of legal professionals. By employing machine learning and artificial intelligence, the platform analyzes historical judicial decisions to identify patterns that can forecast the results of future cases. This capability allows legal practitioners to utilize relevant case law effectively, ultimately saving time and reducing costs associated with legal research. The platform is designed to improve productivity, enabling users to concentrate on higher-value tasks within their practice.

Onyx Motion is a developer focused on enhancing the outdoor experience for paddle sports enthusiasts. The company creates a variety of paddle sports equipment, including paddleboards and gear, and provides instructional content aimed at improving water sports performance. Additionally, Onyx Motion develops sports coaching applications compatible with Apple and Android smartwatches, further supporting users in their pursuit of outdoor activities. By combining quality equipment with valuable resources, Onyx Motion seeks to elevate the skills and enjoyment of individuals engaged in paddle sports.

PhenoTips is a computer software company based in Ontario, Canada, founded in 2014. It specializes in providing solutions for clinical genetics, phenotyping, and human phenotype ontology. The company offers software designed for clinical use that integrates seamlessly with existing electronic health records. PhenoTips' technology aims to enhance diagnostic accuracy and standardize phenotype recording, facilitating the application of genomic medicine in clinical decision-making and diagnosis.

FlowJEM specializes in the development of polymer microfluidic technology aimed at the rapid and cost-effective prototyping of microfluidic devices. The company provides high-quality plastic microfluidic components made from various thermoplastic materials, ensuring compatibility with specific chemical requirements as well as optical transparency and temperature stability. FlowJEM's technology is tailored for researchers and engineers in the microfluidics field, facilitating the creation of robust devices for diverse applications.

ScarX Therapeutics Inc. is a biotechnology company based in Toronto, Canada, founded in 2012. The company focuses on discovering and developing innovative treatments for dermal scarring, also known as fibrosis. Its lead product, SCX-001, is a topical prescription cream designed to treat and prevent post-surgical scarring, utilizing nefopam, an active pharmaceutical ingredient known for its anti-scarring properties. This product aims to alleviate the physical and psychological impacts of surgical scars, addressing a significant unmet medical need as no clinically-proven prescription treatments currently exist. With over 100 million individuals in developed countries affected by surgical scarring each year, ScarX's target market is substantial, particularly within the cosmetic and reconstructive surgery sectors. The company has recently completed preclinical studies and is preparing to advance SCX-001 into Phase I/IIa clinical trials, with an estimated market potential exceeding $4 billion annually in the U.S. alone. ScarX's technology is based on over 15 years of research led by Dr. Benjamin Alman, emphasizing its commitment to improving surgical outcomes for patients worldwide.

WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer tissues. By making better, more accurate information available about a woman's response to her chemotherapy treatment in weeks, rather than months, WaveCheck creates greater transparency through dialogue between a women and her doctors, empowering her to participate in discussions about whether a given chemotherapy treatment is effective.

AmacaThera Inc. is a clinical-stage biotechnology company based in Toronto, Canada, established in 2016. The company focuses on developing and commercializing an injectable hydrogel technology designed to enhance drug delivery for various medical applications. This innovative platform aims to improve patient outcomes in areas such as post-surgical pain management, cancer treatment, and other challenging therapeutic targets. AmacaThera's technology features a fast-gelling material that transitions from a liquid to a gel under force, combining hyaluronan and methylcellulose. This unique formulation allows for localized and sustained drug delivery, ultimately assisting healthcare providers in effectively managing patients' pain following surgery.

CoHealth is a content creation and distribution platform tailored for health organizations, including healthcare providers and systems. The platform facilitates the development and dissemination of health-related content, enabling these organizations to effectively reach health consumers. It offers features such as hospital information, medication reminders, and personalized task recommendations through a collaboration between personal health managers and healthcare providers. By creating customized digital care pathways for various health conditions, CoHealth ensures that patients receive comprehensive aftercare support following their hospital discharge.

Nuralogix specializes in healthcare analytics by leveraging its patented technology, Transdermal Optical Imaging (TOI™), which extracts facial blood flow information using a conventional video camera. The company's flagship app, Anura™, allows users to monitor their health without the need for traditional wearables or cuffs, making it the first contactless application for measuring blood pressure. Anura™ not only measures blood pressure but also assesses various physiological and psychological indicators, such as heart rate, stress levels, body mass index, and cardiovascular disease risks, all with medical-grade accuracy. This innovative approach enables individuals to track their health conveniently and efficiently, enhancing overall well-being.

Ardra Inc. is a renewable chemicals company based in Toronto, Canada, specializing in the production of petroleum-free specialty chemicals for the personal care and cosmetics industry. Utilizing technology developed at the University of Toronto, Ardra employs model-guided metabolic engineering and synthetic biology to create biocatalysts that convert renewable resources into essential chemicals. The company's flagship product is 1,3-butanediol, a sustainable alternative to petroleum-based counterparts, which is utilized in various applications including cosmetics, food, polymers, and pharmaceuticals. With the cosmetics sector relying heavily on petroleum chemicals, valued at approximately $2.6 billion, Ardra aims to provide environmentally friendly solutions that stabilize and sustain the supply chain while reducing ecological impact.

Encycle Therapeutics is a biotechnology company based in Toronto, Canada, focused on developing drug-like macrocycles and membrane-permeable nacellins through its innovative platform technology. This approach allows for the rapid synthesis of nacellins, which have the potential to effectively target intracellular protein-protein interactions that are difficult to address with traditional small molecules and biologics. Encycle's nacellins can serve as cost-effective, oral alternatives to existing biologics, such as monoclonal antibodies. The company collaborates with various pharmaceutical firms to create a screening library of nacellins, many of which exhibit desirable drug-like properties. Encycle is actively developing nacellins aimed at treating integrin alpha-4-beta-7 related inflammatory bowel disease and SMURF2 associated fibrosis, with a focus on producing orally bioavailable inhibitors that promise improved safety and reduced immunogenicity compared to current biologic therapies targeting the same protein.

LegWorks, Inc. is a social enterprise based in Buffalo, New York, that specializes in designing and manufacturing prosthetic knee joints and complete prosthetic leg solutions for lower-limb amputees globally. Founded in 2013, the company aims to provide these essential components regardless of the amputees' location, social status, or financial means. LegWorks implements a tiered pricing strategy to create accessible options across different markets, ensuring that its products reach both developed and developing regions. The company's prosthetic knee joint features a locking mechanism that prevents bending, facilitating mobility and promoting independence for users, enabling them to navigate their daily lives with confidence.

Syncadian Inc. is focused on developing software solutions in the fatigue management sector. Initially, the company created a mobile application aimed at helping Canadian military personnel prevent jetlag. Building on this foundation, Syncadian is exploring various applications of its technology for diverse groups, including shift workers, military members, and cancer patients. The company aims to provide tools that enable organizations to reduce fatigue-related errors and enhance productivity. Additionally, Syncadian's solutions assist individuals in monitoring and optimizing their sleep quality and patterns, contributing to overall well-being and performance.

ChipCare Corporation, founded in 2009 and based in Toronto, Canada, specializes in developing point-of-care testing and monitoring systems for healthcare applications. The company aims to enhance access to advanced blood tests worldwide through its innovative handheld cell analyzer system, which can conduct multiple diagnostic tests from a single drop of blood. This includes cell counting, protein and enzyme analysis, and pathogen detection. ChipCare's solution integrates patient identification, blood testing, and quality management protocols, making it suitable for both resource-rich and resource-limited settings. The primary revenue stream is expected to come from the sale of disposable test slides, which are critical components of its diagnostic platform. This microfluidic technology enables healthcare providers to perform a variety of tests efficiently, facilitating timely diagnosis and treatment for patients in need.

Flatfab offers software that facilitates the design and fabrication of 3D objects, bridging the gap between digital modeling and traditional craftsmanship. By allowing users to imagine in 3D while working in 2D, Flatfab addresses the challenges of 3D printing, which can be costly and time-consuming, particularly for complex, small-scale projects. The software supports various fabrication methods, including laser cutting and CNC machining, rather than relying solely on 3D printers. With features like interactive verification and real-time model testing, Flatfab empowers designers and hobbyists to work with a range of materials, such as paper, plastic, wood, steel, and stone, enabling them to create intricate 3D objects efficiently.

Nvest is an Internet platform that helps people become smarter investors. Anyone is free to share investment opinions. Nvest evaluates people’s credibility based on the accuracy of their opinions because actual performance speaks louder than credentials. Nvest is currently focusing on stock markets, and will be expanded to many possible investment types. People can express their opinions as buy and sell ratings. The accuracy of each opinion depends on its correctness, magnitude of impact and industry. Nvest wants to consolidate and present only the very valuable investment information to retail investors at the right time. People will be able to access Nvest with any Internet devices. Visit http://www.nvest.me for open beta!

Forbius, also known as Formation Biologics, is a clinical-stage company focused on designing and developing biotherapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, Forbius specializes in creating agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. The company aims to provide highly active inhibitors of these validated pathways, utilizing its expertise in biology and protein engineering technologies to develop novel therapeutic options. Through their innovative approach, Forbius seeks to significantly improve patient outcomes and transform the treatment landscape for challenging diseases.

Vasomune Therapeutics is a biotechnology company focused on developing therapies for diseases linked to blood vessel dysfunction and destabilization. The company's lead compound, Vasculotide, is a Tie2 receptor agonist that aims to address various conditions exacerbated by vascular dysfunction, including cardiovascular, renal, pulmonary, and oncology-related diseases. Established in 2012 as a spin-out from MaRS Innovation and the University of Toronto's Sunnybrook Hospital, Vasomune is translating robust academic research into clinical applications. The company's primary initiatives concentrate on treating acute and chronic kidney diseases, with a particular emphasis on Acute Kidney Injury (AKI), a significant unmet medical need. The decision to target AKI is supported by validated preclinical data indicating that vascular dysfunction is central to the condition. Vasomune’s approach seeks to modify the cellular response to disease, thereby enhancing patient outcomes in the face of vascular-related illnesses.

Granata Decision Systems develops a decision support software platform that aids organizations in making optimal decisions through real-time optimization and scenario analysis. The software employs patent-pending algorithms that enhance the effectiveness of machine learning and analytics. By distilling insights from multiple analyses, Granata's technology allows companies to focus on factors important to their global objectives. This enables organizations to navigate complex, data-driven group decision-making processes by gathering preferences and evaluating options, ultimately maximizing value for relevant stakeholders.

Whirlscape is a company focused on enhancing the texting experience through innovative technology. They offer a mobile keyboard application that streamlines typing by minimizing the keyboard to a one-line format, allowing users to view more of their screen and type more efficiently. The application is designed to work across various device sizes, ensuring a user-friendly experience. Additionally, Whirlscape utilizes machine learning to develop predictive messaging capabilities, creating natural language models that anticipate user input, including text, emojis, stickers, and GIFs. This combination of features aims to improve communication by making it faster and more expressive.

WaveCheck — a painless, non-surgical clinical technique developed by a Sunnybrook Health Sciences Centre oncologist and a Ryerson University physicist and supported by MaRS Innovation — is poised to transform chemotherapy response monitoring for women with breast cancer. WaveCheck combines traditional ultrasound with new software to detect responses to chemotherapy in breast cancer tissues. By making better, more accurate information available about a woman's response to her chemotherapy treatment in weeks, rather than months, WaveCheck creates greater transparency through dialogue between a women and her doctors, empowering her to participate in discussions about whether a given chemotherapy treatment is effective.

ChipCare Corporation, founded in 2009 and based in Toronto, Canada, specializes in developing point-of-care testing and monitoring systems for healthcare applications. The company aims to enhance access to advanced blood tests worldwide through its innovative handheld cell analyzer system, which can conduct multiple diagnostic tests from a single drop of blood. This includes cell counting, protein and enzyme analysis, and pathogen detection. ChipCare's solution integrates patient identification, blood testing, and quality management protocols, making it suitable for both resource-rich and resource-limited settings. The primary revenue stream is expected to come from the sale of disposable test slides, which are critical components of its diagnostic platform. This microfluidic technology enables healthcare providers to perform a variety of tests efficiently, facilitating timely diagnosis and treatment for patients in need.

BlueDot Inc. is a data analytics company based in Toronto, Canada, specializing in infectious disease monitoring and response. Founded in 2008 and formerly known as BioDiaspora Inc., BlueDot employs a combination of artificial intelligence and human expertise to analyze over 190 infectious diseases worldwide. The company provides critical insights by integrating various datasets, including disease outbreaks, healthcare facilities, local mobility patterns, animal populations, and climate data. Its early warning system helps public and private organizations identify potential infectious disease threats, allowing them to respond effectively without overreacting or underreacting. By delivering comprehensive data analytics solutions, BlueDot aims to enhance global preparedness against infectious diseases.

Crowdmark, Inc. is an education technology company based in Toronto, Canada, founded in 2012. It provides a web-based application that enhances the grading and assessment process for educators by bridging paper-based and digital formats. The platform is designed to facilitate both online and in-class assessments, allowing teachers to grade assignments more efficiently while offering constructive feedback to students. By leveraging artificial intelligence, Crowdmark aims to improve learning outcomes and redefine assessment as a constructive dialogue between educators and students. The service is utilized by instructors across various educational levels, including primary, secondary, and tertiary institutions, both in Canada and internationally. Additionally, Crowdmark's system generates valuable insights into grading and learning performance, contributing to an enhanced educational experience.

Treata Smart Solutions is a company based in Toronto, Ontario, that specializes in caregiving technology for memory-impaired adults. Founded in 2012, it offers three innovative products: The Smart Lost Item Finder, The Smart Wandering Assistant, and The Smart Reminder. These devices leverage existing smartphone technology, enhanced with patent-pending hardware and software, to assist caregivers in monitoring the well-being of elderly individuals. The company's solutions aim to improve safety by providing real-time location information and alerts, ensuring that caregivers are promptly informed if a loved one with memory difficulties becomes lost or encounters any issues.

Root2Crown is focused on creating innovative hardware and software solutions that streamline dental risk assessment processes. By enhancing the efficiency, reliability, and accessibility of dental health assessments and diagnoses, the company serves dental schools, practices, and the general public. Its technology not only facilitates effective communication of dental risk but also tracks the progression of dental caries over time, helping to optimize follow-up appointments. This comprehensive approach enables patients to maintain better dental health and supports practitioners in delivering quality care.

TrendMD Inc., founded in 2013 and based in Toronto, Canada, operates a content recommendation engine tailored for scholarly publishers. The company partners with notable scientific publishers, such as Elsevier and Oxford University Press, integrating a JavaScript code into their journal websites to display related article links. This service aims to connect readers, particularly medical professionals, with relevant peer-reviewed content, thereby expediting the dissemination of scientific knowledge. TrendMD's platform generates approximately 500 million recommendations monthly for over 60 million readers. Utilizing a sophisticated algorithm, it creates personalized profiles to enhance user experience and engagement. TrendMD is approaching profitability after its recent participation in a prominent startup accelerator.

Crowdmark, Inc. is an education technology company based in Toronto, Canada, founded in 2012. It provides a web-based application that enhances the grading and assessment process for educators by bridging paper-based and digital formats. The platform is designed to facilitate both online and in-class assessments, allowing teachers to grade assignments more efficiently while offering constructive feedback to students. By leveraging artificial intelligence, Crowdmark aims to improve learning outcomes and redefine assessment as a constructive dialogue between educators and students. The service is utilized by instructors across various educational levels, including primary, secondary, and tertiary institutions, both in Canada and internationally. Additionally, Crowdmark's system generates valuable insights into grading and learning performance, contributing to an enhanced educational experience.

XLV Diagnostics Inc., located in Thunder Bay, Canada, specializes in the development and manufacturing of low-cost, next-generation digital mammography machines aimed at improving access to breast cancer screening in emerging markets such as China, India, and Brazil. The company utilizes innovative X-ray light valve technology to create mammography detectors that are integrated into custom-designed digital mammography systems. This approach allows XLV Diagnostics to provide affordable and high-quality early-stage breast cancer detection services to clients in developing countries, addressing the growing demand for effective diagnostic technology in regions where breast cancer cases are increasing faster than access to screening options.

eQOL is focused on transforming chronic care by shifting it from hospital settings to home environments, addressing the needs of an aging population and increasing healthcare demands. The company has developed a patient-centric medical platform that empowers individuals to manage their daily clinical tasks independently. By leveraging innovative technologies and processes, eQOL aims to enhance the quality of care while promoting patient independence. This approach not only optimizes overall efficiency but also reduces healthcare delivery costs, making the medical process less intimidating for clients. Ultimately, eQOL's mission is to build the necessary infrastructure and solutions that facilitate effective self-care in the home.

Kaypok specializes in developing advanced unstructured text analytics software that enables enterprises to extract valuable insights from various data sources, such as social media, internal data, customer surveys, emails, and blogs. By analyzing this unstructured data, Kaypok provides businesses with actionable knowledge about customer sentiments and the underlying factors influencing analytics. The company's technology enhances user experience and optimizes enterprise applications by transforming complex information into usable insights, thereby supporting organizations in making informed decisions based on comprehensive data analysis.

Bedside Clinical Systems (BCS) facilitates the deployment of innovations in healthcare supporting clinicians in providing safer and more effective care.

CoursePeer is a developer of a cloud-based suite designed to enhance learning, collaboration, and decision-making in both academic and corporate environments. Its highly scalable and integrated tools support a range of activities, including blended learning, video content delivery, quizzes, and live interactions, all within a social network framework that encourages user engagement. The academic version targets universities and colleges, enabling professors to effectively deliver content and foster communication among students while facilitating assessments and course content reviews for accreditation purposes. The corporate version focuses on employee training and certification, providing capabilities for intranet use and advanced performance management. Overall, CoursePeer's solutions aim to empower institutions and businesses to improve their performance and productivity.

Kapplex Inc. is a Toronto-based company that designs, develops, manufactures, and markets point-of-care diagnostic platforms aimed at diagnosing common infectious diseases and cancer. Established in 2012, Kapplex specializes in providing instruments and consumables for use in retail clinics, doctors' offices, urgent care units, and emergency rooms. The company's innovative technology is built on a proprietary Digital Microfluidic (DMF) platform, which simplifies and automates traditional sample preparations and analyses on a single, cost-effective chip. This advancement allows clinicians to rapidly and accurately diagnose diseases during a patient's first visit, thereby improving treatment outcomes and reducing healthcare costs.

OtoSim is a medical simulation platform specifically designed for training in otoscopy and ophthalmoscopy. Developed by a multidisciplinary team of clinicians, educators, and engineers, the OtoSim device addresses deficiencies in current otoscopic training methods. Its value has been validated through scientific research. The platform serves as an effective medical teaching tool, enabling verifiable learning and enhancing diagnostic efficiency for students. Additionally, OtoSim allows multiple units to connect to a single trainer laptop for group training, facilitating accurate and reliable diagnostic training in medical schools. By improving the educational experience, OtoSim aims to advance the competencies of future healthcare professionals in ear and eye diagnostics.

Xagenic Inc. is a Toronto-based molecular diagnostics company focused on developing innovative technology for decentralized and rapid diagnostic testing. The company aims to enhance patient care by enabling on-demand, near-patient molecular testing, which allows clinicians to make informed treatment decisions during the initial consultation. Xagenic's technology facilitates rapid, enzyme-free detection of nucleic acids from clinical samples, yielding results in just 20 minutes. By commercializing a simple and fully automated platform, Xagenic is positioned to revolutionize diagnostic testing by enabling it to be conducted outside of traditional clinical laboratories. The company is also working on tests for infectious diseases that provide clinically actionable results in a timely manner, thereby improving overall healthcare efficiency and reducing costs.